Dravet syndrome begins in early childhood, but following FDA approval of Diacomit (stiripentol) from Biocodex two drugs have been cleared this year to treat the disease in the US and, with multiple other treatment options in the pipeline, one more could be approved in 2019.
Dravet Syndrome: A Rare Epilepsy, Now With Two Approved Treatments
Biocodex's Diacomit – long approved in the EU – just won FDA approval. That brings the number of drugs cleared for Dravet in the US to two, including GW Pharma's recently endorsed Epidiolex, and the R&D pipeline for this rare seizure disorder is growing.
More from New Products
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024